A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.

Thu Feb 21, 2013 8:02am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link


NEW YORK,  February 21, 2013  /PRNewswire/ --

Today, National Traders Association announced new research reports highlighting
Novogen Limited (NASDAQ: NVGN), Sanofi SA (NYSE: SNY), ISIS Pharmaceuticals,
Inc. (NASDAQ: ISIS), Amgen, Inc. (NASDAQ: AMGN) and Gilead Sciences, Inc.
(NASDAQ: GILD). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Novogen Limited Research Report

Novogen's shares jumped 200 percent after a study revealed that its anti-ovarian
cancer drug was not only effective against ovarian cancer cells, it was also
effective against ovarian cancer stem cells. Cancer stem cells have been found
in a range of cancers including ovarian, brain and leukemia, and are resistant
to radiotherapy and typical anti-cancer drugs. They are also normally
responsible for cancer recurrence, the main cause of death among patients. With
this new discovery, Novogen hopes that its new drug, the CS-6 and the super
benzopyran family of drugs to which it belongs, would eventually become a
comprehensive cancer treatment. Many investors have already jumped to buy
shares, expecting that CS-6 would become the catalyst for Novogen's long-term
growth. The Full Research Report on Novogen Limited - including full detailed
breakdown, analyst ratings and price targets - is available to download free of
charge at:


Sanofi SA Research Report

Sanofi's shares rallied after the U.S. Food and Drug Administration (FDA)
accepted lixisenatide for review. Lixisenatide is the first once-daily treatment
of adults with type 2 diabetes mellitus. Lixisenatide has also been approved for
the European Union, and will be launched as Lyxumia later in the first quarter.
This follows regulatory approvals for Kynamro, Zaltrap, and Aubagio.
Additionally, Sanofi's subsidiary Genzyme also announced positive new data from
phase 3 ENGAGE and ENCORE studies of eliglustat tartrate, an investigational
oral therapy for Gaucher disease type 1. With a string of approvals to boast of,
many believe that the pharmaceutical giant will be able to generate strong
revenue in the upcoming quarters.  Warren Buffett is among Sanofi's
shareholders, along with Abrams Capital. The Full Research Report on Sanofi SA -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:


ISIS Pharmaceuticals, Inc. Research Report

ISIS and Genzyme have announced the US Food and Drug Administration (FDA)
approval of their new product, the KYNAMROTM injection.  The injection reduces
low density liproprotein-cholesterol, apoliprotein B, total cholesterol, and
high density lipoprotein-cholesterol in patients with homozygous familial
hypercholesterolemia (HoFH). HoFH is a rare inherited condition which makes the
body unable to remove LDL cholesterol. In  the United States, HoFH occurs in one
in a million individuals, and for patients with this condition, heart attacks,
and death can occur before age 30. Analysts expect that the product will earn 
$400 million  in peak sales, with Isis getting 30 percent to 50 percent of the
profit, depending on total sales. Sanofi, the pharma giant that owns Genzyme,
will be helping to market this product. Moreover, ISIS recently earned  $7.5
million  payment from GlaxoSmithKline for the initiation of the Phase2/3
clinical study of ISIS-TTR, a treatment for transthyretin (TTR) amyloidosis, a
genetic disease characterized by the dysfunction of peripheral nerve or heart
tissues. The Full Research Report on ISIS Pharmaceuticals, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to download
free of charge at:


Amgen, Inc. Research Report

Amgen reported that its late-stage pipeline is advancing, with two pivotal phase
3 trials due this year, five in 2014, and one in 2016. Analysts have been
praising Amgen for its promising pipeline and its solid long-term strategy, with
researchers at the Jefferies Group reiterating their buy rating on the shares of
the company. The world's largest biotechnology company notes six biosimilars as
its next opportunity for growth, hoping that these products would generate a
combined peak of  $41 billion  in global sales. It is also creating a new
manufacturing process that includes launching new manufacturing technologies
that aim to reduce the capital needed to produce products. It is also planning
to expand globally as it launches products in  Japan  by 2016. The Full Research
Report on Amgen, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:


Gilead Sciences, Inc. Research Report

Gilead announced results from the Phase 3 FUSION study of its Hepatitis C drug,
Sofosbuvir. The study concluded that the drug is effective in treating Hepatitis
C patients who could not be cured by existing medications that contained
pegylated interferon. Interferon is an ingredient loaded with side effects that
often led to patients discontinuing therapy. With this, Gilead is on track to
file regulatory applications for the drug in  the United States  and  Europe  in
the second quarter. The results mark a remarkable run for the company after
taking less than 16 months to finish its Phase III phase. The Full Research
Report on Gilead Sciences, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:


Consider National Traders Association

Tired of hearing about the latest, greatest trade opportunity... only to realize
that the ship has long sailed? You need a strong, informative community in your
arsenal. Join the group that has been consistently identifying momentous
situations as they develop - long before they become the next top news on major
financial networks.

Contact:  Demi Lapierre

Email:  press@NationalTradersAssociation.org

Main: +1(702)212-4493

SOURCE  National Traders Association

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.